Table 2.
Patient clinical and demographic characteristics.
| Variables | Diabetes n (%) |
No diabetes n (%) |
p-value |
|---|---|---|---|
| Age | |||
| Mean ± SD | 64 ± 9.28 | 61 ± 11 | 0.49 |
| Median (IQR) | 65 (16) | 60 (17) | |
| Sex | |||
| Female | 7 (14) | 1 (2) | |
| Male | 42 (85) | 53 (97) | 0.026 |
| Race | |||
| White | 41 (83) | 47 (86) | 0.78 |
| Black | 8 (16) | 7 (13) | |
| BMI | |||
| Mean ± SD | 31 ± 6.6 | 30 ± 5.3 | 0.46 |
| Median (IQR) | 30 (7.4) | 29 (4.5) | |
| Preoperative medications | |||
| β-blockers | 34 (69) | 41 (75) | 0.87 |
| ACEi/ARBs | 15 (31) | 22 (41) | 0.79 |
| Diuretics | 21 (43) | 20 (37) | 0.69 |
| CCBs | 10 (20) | 13 (24) | 0.89 |
| Diabetic medications | 43 (87) | 2 (4) | <0.0001 |
| Insulin | 32 (65) | 2 (4) | |
| Metformin | 15 (31) | 0 | |
| Sulfonylureas | 4 (8) | 0 | |
| Glitazones | 1 (2) | 0 | |
| GLP-1 agonist | 2 (4) | 0 | |
| DDP-4 inhibitor | 3 (6) | 0 | |
| Statins | 41 (83) | 46 (84) | 0.94 |
| Nitrates | 19 (39] | 32 (59) | 0.65 |
| Heart failure | 8 (16) | 5 (9) | 0.31 |
| LVEF (%) | 51.8 ± 3.9 | 53.6 ± 6.4 | 0.87 |
Sample size N = 103 for GPx4, N = 61 for HNE-adduct.